an ATP-competitive manner at low nanomolar concentrations and thereby induces mitotic arrest and apoptosis [1] . Polo-Like Kinase 1 (Plk1) is a serine/threonine specific kinase that regulates multiple steps in mitosis and that is essential for progression through mitosis [2] . Numerous lines of evidence suggest that Plk1 is oncogenic through driving cell cycle progression, and overexpression of the gene transforms NIH 3T3 cells [3] . Plk1 is highly expressed in multiple cancers [2, 4, 5] , and in some malignancies expression of Plk1 may be prognostic [4] . Inhibition of the Plk1 blocks proliferation of cancer cells [6, 7] . Blocking of Plk1 activity with small molecule inhibitors such as Bl 2536 and volasertib produced regressions in multiple preclinical adult cancer models [1, 8] . Volasertib has entered clinical evaluation and has advanced to phase 2 testing [9] [10] [11] .
Plk1 is overexpressed in several childhood cancers and cell lines. RNA interference and small molecule inhibitor screens suggest that Plk1 may be a relevant therapeutic target in a variety of pediatric malignancies including neuroblastoma, rhabdomyosarcoma and osteosarcoma [12] [13] [14] . The Pediatric Preclinical Testing Program (PPTP) therefore evaluated volasertib to gain further insight into the role of Plk1 inhibition as a therapeutic strategy for childhood cancers. 
MATERIALS AND METHODS:
In vitro testing: Testing was performed using DIMSCAN [20] , as previously described in a characterized panel of 24 cell lines [15] . Cells were incubated in the presence of volasertib for 96 hours at concentrations from 0.1 nM to 1 µM and analyzed as previously described [16] .
In vivo tumor growth inhibition studies: CB17SC scid -/-female mice (Taconic Farms, Germantown NY), were used to propagate subcutaneously implanted kidney/rhabdoid tumors, sarcomas (Ewing, osteosarcoma, rhabdomyosarcoma), neuroblastoma, and non-glioblastoma brain tumors, while BALB/c nu/nu mice were used for glioma models, as previously described [17] . Human leukemia cells were propagated by intravenous inoculation in female non-obese diabetic (NOD)/scid -/-mice as described previously [18] . Female mice were used irrespective of the patient gender from which the original tumor was derived. All mice were maintained under barrier conditions and experiments were conducted using protocols and conditions approved by the institutional animal care and use committee of the appropriate consortium member. Eight to ten mice were used in each control or treatment group. Tumor volumes were determined and responses were determined using three activity measures as previously described [17] . An in-depth description of the analysis methods is included in the Supplemental Response Definitions section.
Statistical Methods:
The exact log-rank test, as implemented using Proc StatXact for SAS®, was used to compare event-free survival distributions between treatment and control groups. P-values were twosided and were not adjusted for multiple comparisons given the exploratory nature of the studies.
Drugs and Formulation: Volasertib was provided to the Pediatric Preclinical Testing Program by
Boehringer Ingleheim AG, through the Cancer Therapy Evaluation Program (NCI). Volasertib was formulated in sterile saline and stored for up to 7 days at 4°C, protected from light. Volasertib was administered IV at 30 mg/kg (solid tumors) and 15 mg/kg (ALL models) to mice using a q 7 days x 3 schedule with an additional 3 weeks of observation. Volasertib was provided to each consortium investigator in coded vials for blinded testing. A metric used to compare the relative responsiveness of the PPTP cell lines to volasertib is the ratio of Thirty-four of 40 tested xenograft models were considered evaluable for efficacy. Lines inevaluable because of toxicity included four ALL xenografts (ALL-4, ALL-7, ALL-31, and MLL7) and two rhabdomyosarcoma xenografts (Rh30 and Rh30R). Testing was repeated for the latter two xenografts and volasertib was tolerated in the repeat testing. Complete details of testing are provided in Supplemental tempting to speculate that the strong cell cycle progression drive provided by MYCN plays a role in sensitizing neuroblastoma cells to selected agents that block mitotic progression. Of some interest is that all of the solid tumors demonstrating regressions were derived from patients that had failed prior therapies.
RESULTS

In vitro testing:
For the ALL panel that utilized NOD-SCID mice, toxicity limited the evaluation of volasertib activity even though a lower dose was used compared to that employed for the solid tumor panels (15 mg/kg versus 30 mg/kg). Volasertib showed clear anti-leukemia activity against the ALL panel, with a CR noted in one evaluable model and with several inevaluable models that would have been coded PR or CR if less toxicity had been observed. However, the depth of remissions induced by the three weeks of volasertib was not deep, as low levels of leukemia cells were commonly observed in the peripheral blood and as regrowth occurred shortly after treatment was stopped in most cases.
Volasertib has entered clinical testing in adults. A phase 1 trial in adults with progressive advanced or metastatic solid tumors evaluated volasertib as a single 1-hour infusion administered every 3 weeks
[24]. Reversible hematological toxicity was the main side-effect, with thrombocytopenia, neutropenia, and febrile neutropenia constituting the main dose-limiting events. The recommended phase 2 dose was 300 mg, and three patients from among 46 treated with volasertib at doses of 300 mg or higher achieved confirmed partial response. A phase 2 trial for patients with advanced or metastatic urothelial cancer evaluated volasertib at 300 mg using the every three week schedule with the option for dose escalation to 350 mg if the initial course was well tolerated [10] . Partial response was observed in 14%
of patients (7 of 50), with a median duration of response of 30 weeks. Volasertib has also been studied in adults with AML, both as a single agent and in combination with low-dose cytarabine [11, 25] . Seven out of 32 patients treated with volasertib plus low-dose cytarabine achieved a complete remission in the phase 1 trial of this combination [25] . Preliminary phase 2 data demonstrate a significantly improved CR/CRi rate and a trend for EFS benefit for volasertib plus low-dose cytarabine compared with lowdose cytarabine alone in patients with newly diagnosed AML ineligible for intensive treatment [11] . Together with differences in the schedules of administration between rodents and in phase 2 trials (weekly x 3 versus every 3 weeks, respectively), exposures in rodents that lead to regressions may be greater than can be achieved clinically. For responding tumor models, future experiments could address whether responsiveness is maintained with doses/schedules more closely related to the human experience. The observation of higher volasertib exposure in the mouse compared to the human makes it unlikely that the PPTP results represent an under-prediction of the activity of volasertib against the selected childhood cancers evaluated, and the possibility of over-prediction needs to be considered. A caveat that applies to this statement is that pharmacokinetic parameters other than systemic exposure may be more relevant to volasertib activity than AUC and these parameters may be less different between mouse and man than AUC. 1 Tumor Volume T/C value: Relative tumor volumes (RTV) for control (C) and treatment (T) mice were calculated at day 21 or when all mice in the control and treated groups still had measurable tumor volumes (if less than 21 days). The T/C value is the mean RTV for the treatment group divided by the mean RTV for the control group. High activity = T/C < 0.15; Intermediate activity = T/C < 0.45 but > 0.15; and Low activity = T/C > 0.45. 2 Objective response measures are described in detail in the Supplemental Response Definitions. PD1 = progressive disease with EFS T/C ≤ 1.5, and PD2 = progressive disease with EFS T/C > 1.5.
3 EFS T/C values = the ratio of the median time to event of the treatment group and the median time to event of the respective control group. High activity requires: a) an EFS T/C > 2; b) a significant difference in EFS distributions, and c) a net reduction in median tumor volume for animals in the treated group at the end of treatment as compared to at treatment initiation. Intermediate activity = criteria a) and b) above, but not having a net reduction in median tumor volume for treated animals at the end of the study. Low activity = EFS T/C < 2. 4 
